Barclays Lowers its Price Target on Hims & Hers Health, Inc. (HIMS) to $25 and Keeps an Overweight Rating

Barclays Lowers its Price Target on Hims & Hers Health, Inc. (HIMS) to $25 and Keeps an Overweight Rating

📰 Original Source

Read full article at Finance →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.